AIHL.F Stock Overview

Engages in the manufacture, marketing, and distribution of healthcare products to private and public sectors in Southern Africa and India. More details

AIHL.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	5/6
Financial Health	6/6
Dividends	4/6

Rewards

Price-To-Earnings ratio (9.2x) is below the US market (16.4x)

Earnings grew by 12.3% over the past year

Risk Analysis

Shares are highly illiquid

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

Adcock Ingram Holdings Limited Competitors

SIGA Technologies

NasdaqGM:SIGA

US$428.4m

Procaps Group

NasdaqGM:PROC

US$279.8m

Phibro Animal Health

NasdaqGM:PAHC

US$876.5m

biote

NasdaqGM:BTMD

US$216.6m

Price History & Performance

Summary of share price highs, lows and changes for Adcock Ingram Holdings
Historical stock prices
Current Share Price	R2.45
52 Week High	R2.45
52 Week Low	R2.45
Beta	0.28
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-30.00%

Recent updates

Shareholder Returns

	AIHL.F	US Pharmaceuticals	US Market
7D	0%	3.0%	2.8%
1Y	n/a	8.9%	24.6%

Return vs Industry: Insufficient data to determine how AIHL.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AIHL.F performed against the US Market.

Price Volatility

Is AIHL.F's price volatile compared to industry and market?
AIHL.F volatility
AIHL.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AIHL.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine AIHL.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1890	n/a	Andy Hall	www.adcock.co.za

Adcock Ingram Holdings Limited, together with its subsidiaries, engages in the manufacture, marketing, and distribution of healthcare products in South Africa, the United States, Canada, the United Kingdom, rest of Europe, and internationally. It operates through four divisions: Consumer, Over the Counter (OTC), Prescription, and Hospital Products and Services. The company is involved in the sale of various healthcare, personal care, and homecare products through FMCG retailers and corporate pharmacies; OTC medicinal products through corporate and independent pharmacies; branded and generic prescription products, and specialized instrumentation and surgical products; and hospital products in oral solid dosage formulations, syrups, intravenous, and injectable dosage forms.

Adcock Ingram Holdings Limited Fundamentals Summary

How do Adcock Ingram Holdings's earnings and revenue compare to its market cap?
AIHL.F fundamental statistics
Market cap	US$442.59m
Earnings (TTM)	US$47.98m
Revenue (TTM)	US$487.67m

9.2x

P/E Ratio

0.9x

P/S Ratio

Is AIHL.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AIHL.F income statement (TTM)
Revenue	R9.13b
Cost of Revenue	R5.98b
Gross Profit	R3.15b
Other Expenses	R2.25b
Earnings	R898.41m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	5.88
Gross Margin	34.53%
Net Profit Margin	9.84%
Debt/Equity Ratio	0.2%

How did AIHL.F perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

45%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/11/13 23:05
End of Day Share Price	2023/08/16 00:00
Earnings	2023/06/30
Annual Earnings	2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adcock Ingram Holdings Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dan Leech	BNP Paribas Securities (Asia)
Marcelle Jankelow	Citigroup Inc
Mark Wadley	Credit Suisse